Verve Therapeutics Inc is a biotechnology business based in the US. Verve Therapeutics shares (VERV) are listed on the NASDAQ and all prices are listed in US Dollars. Verve Therapeutics employs 113 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $15.50 |
|---|---|
| 52-week range | $10.70 - $78.00 |
| 50-day moving average | $14.69 |
| 200-day moving average | $31.33 |
| Wall St. target price | $53.83 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.58 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $15.5 from 2022-06-29
| 1 week (2022-06-24) | -8.28% |
|---|---|
| 1 month (2022-06-01) | 7.34% |
| 3 months (2022-04-01) | -31.14% |
| 6 months (2021-12-31) | -57.96% |
| 1 year (2021-07-01) | -70.83% |
|---|---|
| 2 years (2020-06-27) | N/A |
| 3 years (2019-06-27) | N/A |
| 5 years (2017-06-27) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -25.85% |
| Return on equity TTM | -57.91% |
| Profit margin | 0% |
| Book value | $6.81 |
| Market capitalisation | $822.4 million |
TTM: trailing 12 months
We're not expecting Verve Therapeutics to pay a dividend over the next 12 months.
Verve Therapeutics, Inc. , a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc. ; a development and option agreement with Acuitas Therapeutics, Inc. ; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.